Korea Centers for Disease Control and Prevention. Korea National Health and Nutrition Examination Survey [Internet]. Seoul: Korea Centers for Disease Control and Prevention; 2015 [cited 2016 Dec 21].
Ha KH, Kim DJ. Trends in the diabetes epidemic in Korea. Endocrinol Metab (Seoul) 2015; 30: 142-6.
Lee YH, Bang H, Kim HC, Kim HM, Park SW, Kim DJ. A simple screening score for diabetes for the Korean population: development, validation, and comparison with other scores. Diabetes Care 2012; 35: 1723-30.
Valdés-Ramos R, Guadarrama-López AL, Martínez-Carrillo BE, BenítezArciniega AD. Vitamins and type 2 diabetes mellitus. Endocr Metab Immune Disord Drug Targets 2015; 15: 54-63.
O’Connell BS. Select vitamins and minerals in the management of diabetes. Diabetes Spectrum 2001; 14: 133-48.
Batuca JR, Amaral MC, Favas C, Paula FS, Ames PRJ, Papoila AL, et al. Extendedrelease niacin increases anti-apolipoprotein A-I antibodies that block the antioxidant effect of high-density lipoprotein-cholesterol: the EXPLORE clinical trial. Br J Clin Pharmacol 2017; 83: 1002-10.
Pang J, Chan DC, Hamilton SJ, Tenneti VS, Watts GF, Barrett PH. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statintreated patients with type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2014; 34: 427-32.
Elam MB, Hunninghake DB, Davis KB, Garg R, Johnson C, Egan D, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 2000; 284:1263-70.
Ooi EM, Watts GF, Chan DC, Pang J, Tenneti VS, Hamilton SJ, et al. Effects of extended-release niacin on the postprandial metabolism of Lp(a) and ApoB-100-containing lipoproteins in statin-treated men with type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2015; 35: 2686-93.
Brinton EA, Triscari J, Brudi P, Chen E, Johnson-Levonas AO, Sisk CM, et al. Effects of extended-release niacin/laropiprant on correlations between apolipoprotein B, LDL-cholesterol and non-HDL-cholesterol in patients with type 2 diabetes. Lipids Health Dis 2016; 15: 116.
Sorrentino SA, Besler C, Rohrer L, Meyer M, Heinrich K, Bahlmann FH, et al. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extendedrelease niacin therapy. Circulation 2010; 121: 110-22.
Garg A, Sharma A, Krishnamoorthy P, Garg J, Virmani D, Sharma T, et al. Role of niacin in current clinical practice: a systematic review. Am J Med 2017; 130: 173-87.
Bays HE, Brinton EA, Triscari J, Chen E, Maccubbin D, MacLean AA, et al. Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control. Vasc Health Risk Manag 2015; 11: 165-72.
Goldie C, Taylor AJ, Nguyen P, McCoy C, Zhao XQ, Preiss D. Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials. Heart 2016; 102: 198-203.
Liu M, Li L, Chu J, Zhu B, Zhang Q, Yin X, et al. Serum N(1)-methylnicotin amide is associated with obesity and diabetes in Chinese. J Clin Endocrinol Metab 2015; 100: 3112-7.
Kannt A, Pfenninger A, Teichert L, Tönjes A, Dietrich A, Schön MR, et al. Association of nicotinamide-N-methyltransferase mRNA expression in human adipose tissue and the plasma concentration of its product, 1-methylnicotinamide, with insulin resistance. Diabetologia 2015; 58: 799-808.
Zhou SS, Li D, Sun WP, Guo M, Lun YZ, Zhou YM, et al. Nicotinamide overload may play a role in the development of type 2 diabetes. World J Gastroenterol 2009; 15: 5674-84.
Collins PD, Sattar N. Glycaemic effects of non-statin lipid-lowering therapies. Curr Cardiol Rep 2016; 18: 133.
Sazonov V, Maccubbin D, Sisk CM, Canner PL. Effects of niacin on the incidence of new onset diabetes and cardiovascular events in patients with normoglycaemia and impaired fasting glucose. Int J Clin Pract 2013; 67: 297302.
Ministry of Health and Welfare. The Korean Nutrition Society. Dietary Reference Intakes for Koreans [Internet]. Sejong: Ministry of Health and Welfare. The Korean Nutrition Society; 2015 [cited 2016 Nov 15].
Park SH, Lee HM, Yoon EK, Min CS, Kim HJ, Jun EA, et al. Niacin upper level recommendation and exposure assessment of foods and multivitamin drugs. Journal of Food Hygiene and Safety 2005; 20: 77-82.
McCormick DB, Shills ME, Young VR, et al. Modern nutrition in health and disease. Philadelphia: Lea & Felbiger; 1988. p. 370-5.
Scientific Committee on Food of European Commission. Opinion of the Scientific Committee on Food on the tolerable upper intake levels of nicotinic acid and nicotinamide (niacin). European Commission 2002; 1-20.
HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014; 371: 203-12.
Guyton JR, Fazio S, Adewale AJ, Jensen E, Tomassini JE, Shah A, et al. Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomized controlled trial. Diabetes Care 2012; 35: 857-60.
Kei A, Elisaf MS. Nicotinic acid: clinical considerations. Expert Opin Drug Saf 2012; 11: 551-64.
Wang N, Guo DY, Tian X, Lin HP, Li YP, Chen SJ, et al. Niacin receptor GPR109A inhibits insulin secretion and is down-regulated in type 2 diabetic islet beta-cells. Gen Comp Endocrinol 2016; 237: 98-108.
Zhou SS, Li D, Zhou YM, Sun WP, Liu QG. B-vitamin consumption and the prevalence of diabetes and obesity among the US adults: population based ecological study. BMC Public Health 2010; 10: 746.
Backes JM, Padley RJ, Moriarty PM. Important considerations for treatment with dietary supplement versus prescription niacin products. Postgrad Med 2011; 123: 70-83.